Physician profile
John M Williams
NPI 1811984719
$15,895.38
in general payments reported to CMS, 2019-2025
31 companies · $724 in 2025
The $724 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,808 · 2020: $1,420 · 2021: $2,445 · 2022: $3,638 · 2023: $2,559 · 2024: $3,302 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,901 · Travel and Lodging: $2,649 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,900.62 |
| Travel and Lodging | $2,648.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $5,388.65 | 2019-2024 | |
| Medtronic, INC. | $2,076.65 | 2021-2025 | Corevalve Evolut R, Micra, Capsurefix Novus Mri Surescan |
| Abbott Laboratories | $1,572.81 | 2020-2025 | Cardiomems, Dragonfly Opstar, Mitraclip |
| Medtronic Vascular, INC. | $1,273.10 | 2019-2020 | |
| Amgen INC. | $963.83 | 2020-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $846.66 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $466.30 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $420.94 | 2019-2023 | Farxiga |
| Kowa Pharmaceuticals America, INC. | $352.46 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $349.34 | 2020-2024 | Xarelto |
| Pfizer INC. | $297.14 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $261.72 | 2021-2025 | Verquvo |
| Amarin Pharma, INC. | $205.30 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.69 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $176.60 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $171.44 | 2023-2024 | Ozempic, Rybelsus |
| Irhythm Technologies, INC. | $162.92 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Regeneron Healthcare Solutions, INC. | $132.68 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $112.47 | 2021-2025 | Uptravi, Opsynvi |
| Boston Scientific Corporation | $72.65 | 2024-2025 | Watchman Access System |
| Baxter Healthcare | $58.18 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Lexicon Pharmaceuticals, INC. | $55.68 | 2023-2024 | Inpefa |
| Atricure, INC. | $47.25 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.00 | 2022-2024 | |
| Esperion Therapeutics, INC. | $37.64 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $37.11 | 2019 | |
| Medicure Pharma INC. | $35.49 | 2024 | Zypitamag |
| Abiomed | $33.66 | 2024 | Impella |
| Cashflow Solutions, LLC | $20.96 | 2023 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Kiniksa Pharmaceuticals International, Plc | $20.28 | 2024 | Arcalyst |
| Lundbeck LLC | $17.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.